BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20210101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220421
DTEND;VALUE=DATE:20220701
DTSTAMP:20260516T022140
CREATED:20220425T094247Z
LAST-MODIFIED:20220519T120013Z
UID:33903-1650499200-1656633599@www.pharmajournalist.com
SUMMARY:CPhI & P-MEC China Virtual Expo Connect
DESCRIPTION:This year CPhI & P-MEC China returns as a SMART event\, combining 2 months of online event with a 3-day in-person event to help you connect for an extended period. \n \n“Virtual Expo Connect”\, to be held from 21st April – 30th June 2022\, is the digital extension of the physical CPhI & P-MEC China event that offers an online alternative for global pharma professionals. \nPowered by PharmaSources.com\, Virtual Expo Connect builds the online platform adding valued services and infinite opportunities to connect\, learn\, trade and grow. \nTo know more visit: https://www.pharmasources.com/vec2022
URL:https://www.pharmajournalist.com/event/cphi-p-mec-china-virtual-expo-connect-2/
LOCATION:Online
ORGANIZER;CN="Informa Markets":MAILTO:Yingqi.shi@imsinoexpo.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220627
DTEND;VALUE=DATE:20220630
DTSTAMP:20260516T022140
CREATED:20220407T094504Z
LAST-MODIFIED:20220407T094504Z
UID:33743-1656288000-1656547199@www.pharmajournalist.com
SUMMARY:3rd TCR-based Therapies for Solid Tumors Summit
DESCRIPTION:Are you using TCRs to target solid tumors yet? \nWith Immunocore having achieved commercialization for the first TCR therapy and Adaptimmune hot on their tail\, 2022 is fast becoming the year for TCRs. \nJoin the TCR-based Therapies for Solid Tumors Summit (June 27-29) to gain knowledge to accelerate the clinical development and improve the safety of these game-changing cell therapies. \nFeaturing 24+ expert speakers\, over 80% of whom are new for 2022\, this summit will address the toughest challenges in TCR development\, such as improving TCR discovery and efficacy\, combating the tumor microenvironment\, optimizing target selection and advancing manufacturing\, preclinical and clinical processes. \nJoin leaders in the field\, including Adaptimmune\, Iovance and TScan as they examine methods to prevent cross reactivity\, increase cell fitness and infiltration\, improve therapy safety and ultimately overcome the hurdles holding back these game-changing treatments from patients in need. \nFind out more in the Event Guide: https://ter.li/sa0pnw
URL:https://www.pharmajournalist.com/event/3rd-tcr-based-therapies-for-solid-tumors-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220628
DTEND;VALUE=DATE:20220701
DTSTAMP:20260516T022140
CREATED:20220427T101322Z
LAST-MODIFIED:20220427T101322Z
UID:33919-1656374400-1656633599@www.pharmajournalist.com
SUMMARY:11th Annual HPAPI Summit
DESCRIPTION:Undoubtedly\, the past two years have changed the pharma industry forever; new modalities are dominating pharma pipelines\, drugs are increasing in potency\, and the restrictions around product quality are tighter than ever before. \nIt is integral that the HPAPI community comes together to apply expertise in ensuring operator safety\, alongside product quality\, to the future of hazardous drug production and fully understand this new landscape\, and regulatory environment. Built in collaboration with industry experts\, the HPAPI Summit provides end-to end coverage tackling; development\, commercial manufacturing & tech transfer\, occupational toxicology\, industrial hygiene & EHS\, across small molecules\, large molecules\, drug conjugates & ATMP\, for a holistic approach to bullet-proofing your hazardous drug production. \nWith sessions championed from the likes of Merck\, Bayer\, AstraZeneca\, Takeda and more\, don’t miss this opportunity to reconnect\, reassess and re-enforce your risk management for your potent pipeline and production at the longest standing and largest global summit for highly potent API’s & hazardous drugs. \nSave up to $700 on your event pass when you book before Friday\, May 20. \nGroup discounts of up to 20% are also available when you bring your team! \nTo know more visit: https://ter.li/3csco9
URL:https://www.pharmajournalist.com/event/11th-annual-hpapi-summit/
LOCATION:Hyatt Regency Boston\, One Ave. de Lafayette\, Boston\, MA\, 02111\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR